Abstract
Epidemiological and clinical evidence indicates that obesity-associated metabolic dysfunction increases the risk of depression, which is often resistant to conventional antidepressant therapies. Elucidating targeted mechanisms underlying obesity-induced depression is therefore essential for developing effective interventions. Accumulating evidence identifies neuroinflammation as a central link between obesity and depressive disorders. Obesity-driven inflammatory signaling disrupts multiple neurobiological processes implicated in depression, thereby contributing to the onset and progression of inflammatory depression. Polyphenols, a diverse class of plant-derived secondary metabolites, have demonstrated neuroprotective properties, largely attributed to their anti-neuroinflammatory effects. By modulating inflammatory pathways and restoring neurobiological homeostasis, polyphenols may represent a promising therapeutic strategy for obesity-related depression. This review summarizes the pathophysiological mechanisms through which obesity induces neuroinflammation and subsequently promotes depressive symptoms. It further evaluates current evidence regarding the efficacy and effective dosing of polyphenols in attenuating inflammatory signaling and alleviating obesity-associated inflammatory depression. Given their anti-neuroinflammatory potential, polyphenols may serve as a valuable adjunctive approach for the management of obesity-induced depression.

This publication has 108 references indexed in Scilit: